Corcept's Q2 2025 saw 60% therapy demand growth despite bottlenecks. Despite near-term operational risks, we maintain ...

Luxfer thrives on defense, aerospace, and clean-energy demand, with strong financials. See here to know why we are bullish on ...

Valvoline's growth strategy remains strong despite macroeconomic challenges. VVV stock has continued to expand the franchise ...

Day One Biopharmaceuticals poised for growth with OJEMDA success and FIREFLY-2 catalysts. See here to know why we are bullish ...

Baron Capital highlights biotech and robotic surgery as key growth drivers in Q2. See which stocks surged, which stumbled, ...

CoreWeave thrives as a leading AI infrastructure provider, fueled by GenAI growth and a $11.9B OpenAI deal. Read here for ...

Nuveen S&P 500 Dynamic Overwrite Fund underperforms its peers and lacks downside protection. See here to know why we are ...

Wayfair's +5% net revenue growth in Q2 2025 was quite good, and it mentioned strong Q3 2025 QTD results too. Read more on W ...

Flowers faces sharp revenue declines and high losses amid macroeconomic challenges. Read here for an in-depth analysis of ...

Despite short-term headwinds, UnitedHealth offers strong upside in the medium term. See more o UNH stock's Q2 challenges and ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Occidental Petroleum's first direct air capture hub is on track to begin capturing carbon dioxide later this year, CEO Vicki ...